Search
Search Results
-
Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent...
-
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
BackgroundImmunohistochemistry (IHC) and in situ hybridization (ISH) remain standard biomarkers for therapeutic decisions in human epidermal growth...
-
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
BackgroundPrecision medicine with gene panel testing based on next-generation sequencing for patients with cancer is being used increasingly in...
-
HER2-targeted therapies in cancer: a systematic review
Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is...
-
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
BackgroundOverexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer...
-
HER Receptor, Current, and Emerging Therapeutic Targets
The human epidermal growth factor receptor (HER/ErbB) family consists of four members: HER-1 or epidermal growth factor receptor (EGFR), HER-2,...
-
MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer
PurposeIn this study, we assessed whether the overexpression of MAP3K1 promotes the proliferation, migration, and invasion of breast cancer cells,...
-
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
BackgroundBreast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough...
-
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
HER3 (human epidermal growth factor receptor 3) acts through heterodimerization with EGFR (epidermal growth factor receptor) or HER2 to play an...
-
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual...
-
Clinicopathological features and prognosis of patients with HER2-low breast cancer
BackgroundLow human epidermal growth factor receptor 2 (HER2) expression is an emerging concept in breast cancer that is defined as...
-
Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are the members of protein tyrosine kinase family....
-
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
BackgroundReal-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in...
-
Neratinib for HER2-positive breast cancer with an overlooked option
Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain...
-
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases
BackgroundAccurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical...
-
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance....
-
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
BackgroundEvaluation of human epidermal growth factor receptor 2 (HER2) overexpression caused by erb-b2 receptor tyrosine kinase 2 ( ERBB2 )...
-
TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer
Human epidermal growth factor receptor 2-positive (HER2 + ) breast cancer is correlated with poor prognosis, the current treatment of which is still...
-
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
BackgroundConsidering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2...
-
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
BackgroundThe role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its...
